Injection Site Irritation Completed Phase 4 Trials for Rocuronium (DB00728)

IndicationStatusPhase
DBCOND0063115 (Injection Site Irritation)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01824758Effect of Esmolol on Pain Due to RocuroniumSupportive Care